You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the AVYCAZ (avibactam sodium; ceftazidime) Drug Profile, 2024 PDF Report in the Report Store ~

AVYCAZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Generic Entry Outlook for Avycaz

Avycaz was eligible for patent challenges on February 25, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 15, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for AVYCAZ
Drug patent expirations by year for AVYCAZ
Drug Prices for AVYCAZ

See drug prices for AVYCAZ

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AVYCAZ
Generic Entry Date for AVYCAZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AVYCAZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
Michigan State UniversityPhase 1
University of Southern CaliforniaPhase 4

See all AVYCAZ clinical trials

Pharmacology for AVYCAZ

US Patents and Regulatory Information for AVYCAZ

AVYCAZ is protected by nine US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AVYCAZ is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AVYCAZ

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS

Heterocyclic compounds as inhibitors of beta-lactamases
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting AVYCAZ

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Try a Trial

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AVYCAZ

When does loss-of-exclusivity occur for AVYCAZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6972
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 12270051
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2013032415
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 80403
Estimated Expiration: ⤷  Try a Trial

China

Patent: 3649051
Estimated Expiration: ⤷  Try a Trial

Patent: 5294690
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 21005
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 96615
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 9815
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 23800
Estimated Expiration: ⤷  Try a Trial

Patent: 42462
Estimated Expiration: ⤷  Try a Trial

Patent: 14517027
Estimated Expiration: ⤷  Try a Trial

Patent: 17036307
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 5730
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 1020
Estimated Expiration: ⤷  Try a Trial

Patent: 13014114
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 10091
Estimated Expiration: ⤷  Try a Trial

Patent: 69076
Estimated Expiration: ⤷  Try a Trial

Patent: 14101244
Estimated Expiration: ⤷  Try a Trial

Patent: 17102358
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 5289
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2143660
Estimated Expiration: ⤷  Try a Trial

Patent: 140040748
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 60404
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 65706
Estimated Expiration: ⤷  Try a Trial

Patent: 1317238
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AVYCAZ around the world.

Country Patent Number Title Estimated Expiration
Turkey 200400859 ⤷  Try a Trial
Eurasian Patent Organization 200400981 ⤷  Try a Trial
Brazil 112013032415 "trans-7-oxo-6-(sulfoóxi)-1,6-diazabiciclo[3,2,1]octano-2-car-boxiamida e ({[(2s,5r)-2-carbamoil-7-oxo-1,6-diazabiciclo[3.2.1]oct-6-5 il]óxi}sulfonil)oxidanida, processos para sua preparação, e intermediários". ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AVYCAZ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1480644 PA2016037,C1480644 Lithuania ⤷  Try a Trial PRODUCT NAME: FARMACINIS MISINYS ARBA DERINYS, APIMANTIS KAIP VEIKLIUOSIUS INGREDIENTUS (1) CEFTAZIDIMA ARBA JO DRUSKA IR (2) AVIBAKTAMA ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
1480644 1690059-9 Sweden ⤷  Try a Trial PRODUCT NAME: PHARMACEUTICAL MIXTURE OR ASSOCIATION THAT INCLUDES AS ACTIVE INGREDIENTS: (1) CEFTAZIDIME OR A SALT THEREOF, AND (2) AVIBACTAM OR A SALT THEREOF; REG. NO/DATE: EU/1/16/1109 20160628
1480644 2016C/069 Belgium ⤷  Try a Trial PRODUCT NAME: ZAVICEFTA (COMBINAISON DE CEFTAZIDIME ET AVIBACTAM); AUTHORISATION NUMBER AND DATE: EU/1/16/1109/001 20160628
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.